U.S. Diversified Financial Stock News

NYSE:VRTS
NYSE:VRTSCapital Markets

How Virtus’ New Silvant Growth Opportunities ETF (VGRO) At Virtus Investment Partners (VRTS) Has Changed Its Investment Story

In late 2025, Virtus Investment Partners expanded its actively managed ETF lineup by launching the Virtus Silvant Growth Opportunities ETF (VGRO), run by Silvant Capital Management and built on bottom-up fundamental research. This fund’s “all-weather” growth approach, combining secular and cyclical growth stocks without a strict style or factor bias, underlines Virtus’ emphasis on differentiated active management within its multi-manager ETF platform. With this new actively managed growth...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch

Omeros (OMER) drew fresh investor attention after the U.S. Food and Drug Administration approved YARTEMLEA for hematopoietic stem cell transplant associated thrombotic microangiopathy, and the company is preparing a U.S. launch and related reimbursement infrastructure. See our latest analysis for Omeros. The FDA approval appears to be the main backdrop for recent price action, with a 30 day share price return of 50.97% and a 90 day share price return of 268.92%. Meanwhile, the 1 year total...
NasdaqCM:DCTH
NasdaqCM:DCTHMedical Equipment

Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative

Delcath Systems recently reported publication of subgroup analyses from its phase 3 FOCUS study of the HEPZATO KIT for unresectable metastatic uveal melanoma in the Journal of Cancer Research and Clinical Oncology, detailing efficacy and safety outcomes across multiple patient categories. The data highlight that patients with lower tumor burden and low or normal LDH experienced meaningfully longer progression-free and overall survival, with many responses emerging only after several...